Anixa Biosciences to Participate in the 2022 Virtual Growth Conference Hosted by M-Vest, a Division of Maxim Group LLC

Rhea-AI Summary

Anixa Biosciences, Inc. (NASDAQ: ANIX) announced its participation in the 2022 Virtual Growth Conference hosted by M-Vest from March 28-30, 2022. The presentation will be led by Mike Catelani, the Chief Operating Officer and Chief Financial Officer, who will provide an overview of the company's business and program updates. Anixa focuses on developing cancer treatments and vaccines, including an innovative CAR-T immunotherapy and vaccines targeting triple negative breast cancer and ovarian cancer. For more details, visit www.anixa.com.

SAN JOSE, Calif., March 17, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the Company will present at the 2022 Virtual Growth Conference, hosted by M-Vest, a division of Maxim Group LLC, on March 28^th – 30^th from 9:00 am – 5:00 pm EDT.

During this virtual conference, Anixa's Chief Operating Officer and Chief Financial Officer, Mike Catelani, will provide an overview of Anixa's business and an update on the Company's programs. To attend the conference and view the presentation, sign up to become an M-Vest member here.

About Anixa Biosciences, Inc.
Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a COVID-19 therapeutics program focused on inhibiting certain viral protein function. The company's vaccine portfolio includes a vaccine to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – and a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against specific proteins that have been found to be expressed in certain forms of cancer. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Additional information is available at www.anixa.com.

Contacts

Company Contact:
Mike Catelani
Chief Operating Officer and Chief Financial Officer
mcatelani@anixa.com
408-708-9808

Media:
Slavena Salve Nissan, M.D.
LifeSci Communications
snissan@lifescicomms.com
718-483-4440

Investors:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
646-751-4363

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-to-participate-in-the-2022-virtual-growth-conference-hosted-by-m-vest-a-division-of-maxim-group-llc-301504842.html

SOURCE Anixa Biosciences, Inc.

FAQ

What is Anixa Biosciences presenting at the 2022 Virtual Growth Conference?

Anixa Biosciences will present an overview of its business and program updates at the 2022 Virtual Growth Conference from March 28 to 30, 2022.

Who will represent Anixa Biosciences at the Virtual Growth Conference?

Mike Catelani, Chief Operating Officer and Chief Financial Officer, will represent Anixa Biosciences during the conference.

When is the 2022 Virtual Growth Conference hosted by M-Vest?

The 2022 Virtual Growth Conference hosted by M-Vest is scheduled for March 28-30, 2022.

What technologies does Anixa Biosciences focus on?

Anixa Biosciences focuses on cancer immunotherapy, including CAR-T technology, and vaccines for breast and ovarian cancer.

Where can I find more information about Anixa Biosciences?

More information about Anixa Biosciences is available at their website: www.anixa.com.